Coronary heart disease is a common and serious threat to the health and lives of patients. Its occurrence is associated with dyslipidemia, inflammatory response, diabetes, hypertension and many other causes. The main clinical manifestations are angina pectoris, myocardial infarction, and eventually patients often die from heart failure or ventricular tachycardia/ventricular fibrillation. Ventricular tachycardia/ventricular fibrillation occurs because the patient’s coronary arteries are narrowed or occluded, causing ischemic necrosis of the ventricular muscle, but due to the “interlocking” distribution of the small branches of the coronary vessels in the heart, it is possible that the necrotic scar is intertwined with the surviving myocardium, so that the current that causes the normal heart contraction is transmitted to the If the subtle conditions happen to coincide, ventricular tachycardia or even ventricular fibrillation can occur, leading to panic, shortness of breath, fainting, or even death in severe cases. Currently, in addition to oral amiodarone, sotalol, etc., to control ventricular tachycardia, patients who have fainted or who have been evaluated by a physician as being at high risk for sudden death in the future should be implanted with a miniaturized cardiac defibrillator, or ICD, which cannot eliminate the ventricular tachycardia lesion itself, but can be administered in the event of a malignant ventricular tachycardia. The device itself cannot eliminate the foci of ventricular tachycardia, but can give electric shocks to try to save the patient’s life during an attack of malignant ventricular tachycardia. This is currently the internationally accepted treatment of choice. In addition to not being able to eradicate ventricular tachycardia, it is expensive, has a limited lifespan, can be painful, and can cause rapid deterioration of cardiac function if given frequently over a short period of time. Catheter ablation is another treatment option, which theoretically has the potential to eradicate ventricular tachycardia. We have been performing this technique for ten years and have accumulated the largest series of cases in Asia with good results to date. However, the long-term results remain to be seen, as the disease may progress and theoretically create new ventricular tachycardia lesions. Currently, it is mainly indicated for patients with relatively few ventricular tachycardia lesions and relatively good cardiac function. Ideally, patients with high-risk post-coronary myocardial infarction ventricular tachycardia should have an ICD implanted followed by radiofrequency ablation, thus obtaining “double insurance”. However, the cost to complete these treatments is relatively high, approximately $130,000-$150,000.